FDA investigates heart risks potentially tied to Xolair

07/16/2009 | WebMD

The FDA is investigating a potential link between Genentech's asthma drug Xolair and a heightened risk of heart and cerebrovascular events. The agency clarified that it "is not advising patients to stop taking Xolair at this time" but urged them to be "aware of the risks and benefits described in the prescribing information."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN